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Abstract
Background: Lynch syndrome (LS) is an autosomal dominant inherited cancer syndrome characterized by early
onset cancers of the colorectum, endometrium and other tumours. A significant proportion of DNA variants in LS
patients are unclassified. Reports on the pathogenicity of the c.1852_1853AA>GC (p.Lys618Ala) variant of the MLH1
gene are conflicting. In this study, we provide new evidence indicating that this variant has no significant
implications for LS.
Methods: The following approach was used to assess the clinical significance of the p.Lys618Ala variant: frequency
in a control population, case-control comparison, co-occurrence of the p.Lys618Ala variant with a pathogenic
mutation, co-segregation with the disease and microsatellite instability in tumours from carriers of the variant. We
genotyped p.Lys618Ala in 1034 individuals (373 sporadic colorectal cancer [CRC] patients, 250 index subjects from
families suspected of having LS [revised Bethesda guidelines] and 411 controls). Three well-characterized LS families
that fulfilled the Amsterdam II Criteria and consisted of members with the p.Lys618Ala variant were included to
assess co-occurrence and co-segregation. A subset of colorectal tumour DNA samples from 17 patients carrying
the p.Lys618Ala variant was screened for microsatellite instability using five mononucleotide markers.
Results: Twenty-seven individuals were heterozygous for the p.Lys618Ala variant; nine had sporadic CRC (2.41%),
seven were suspected of having hereditary CRC (2.8%) and 11 were controls (2.68%). There were no significant
associations in the case-control and case-case studies. The p.Lys618Ala variant was co-existent with pathogenic
mutations in two unrelated LS families. In one family, the allele distribution of the pathogenic and unclassified
variant was in trans, in the other family the pathogenic variant was detected in the MSH6 gene and only the
deleterious variant co-segregated with the disease in both families. Only two positive cases of microsatellite
instability (2/17, 11.8%) were detected in tumours from p.Lys618Ala carriers, indicating that this variant does not
play a role in functional inactivation of MLH1 in CRC patients.
Conclusions: The p.Lys618Ala variant should be considered a neutral variant for LS. These findings have
implications for the clinical management of CRC probands and their relatives.
Background
Genetic testing is conducted for diverse purposes, includ-
ing confirmation of diagnosis, risk prediction, carrier test-
ing and reproductive decision-making. The identification
of germ-line mutations in patients with inherited cancer
syndromes enables them to be included in cancer
surveillance programmes. Such programmes are effective
in reducing cancer mortality in the families concerned.
Moreover, family members who do not carry the mutation
can be treated safely as low-risk individuals, avoiding
unnecessary screening and preventing anxiety in the indi-
viduals concerned. Unfortunately, the number of sus-
pected familial cancer cases in which a causative mutation
is identified is far from ideal. All members from a family
with a strong history of cancer and no causative mutation
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detected are included in a surveillance program. Identifica-
tion of mutations depends on the specific syndrome and
the criteria applied to select patients for genetic analyses.
The results of sequence-based genetic tests may be
reported to physicians as: 1) positive, in which a muta-
tion that clearly disrupts gene function is detected and
is highly likely to have clinical consequences; 2) a
genetic variant is detected but it is not known whether
the variant has any effect on gene function that might
confer an increased cancer risk (these variants are
known as variants of uncertain/unclassified significance
or unclassified variants [UVs]); and 3) negative, in which
deleterious variant or UV is detected [1].
The majority of UVs are missense mutations or small
in-frame deletions. The human gene pool harbours a
vast number of rare missense substitutions, 70% of
which are at least mildly deleterious [2]. Integration of
various lines of evidence may help to classify UVs. Infor-
mation on: 1) frequencies in cases and controls, 2) co-
occurrence (in trans) with deleterious mutations, 3) co-
segregation with disease in pedigrees, 4) pathological
factors, 5) amino acid polarity or size, 6) evolutionary
conservation of the residue, 7) splice predictions and 8)
in vitro and/or in vivo functional assays may enable UVs
to be classified as pathogenic or non-pathogenic [3].
Lynch syndrome (MIM# 120435) (LS) is an autosomal
dominant inherited cancer syndrome characterized by early
onset colorectal cancer (CRC), cancer of the endometrium
and tumours of the stomach, pancreas, small intestine,
ovary, bladder and bile duct [4]. LS-associated tumours are
characterized by DNA mismatch repair (MMR) deficiency,
which may be evidenced by microsatellite instability (MSI)
or loss of expression of MMR proteins using immunohisto-
chemistry [5]. The proportion of genetic UVs in LS varies
from 1/5 to 1/3 of all unique variants detected [6].
The MLH1 p.Lys618Ala (c.1852_1853AA>GC) variant
was initially considered a deleterious variant based on
its recurrent presence in LS families, in silico predictions
and in vitro experiments on its functional effect. How-
ever, recent data on its co-segregation with LS have cast
doubt on its clinical significance [6]. In this study, we
provide evidence supporting the contention that this
variant has no significant implications in LS.
The following approach was used to assess the clinical
significance of the p.Lys618Ala variant: frequency in a
control population, case-control and case-case compari-
sons, co-occurrence with a pathogenic mutation, co-seg-
regation with the disease and MSI in tumours from
carrier individuals.
Methods
Controls and sporadic and familial CRC cases
We genotyped the p.Lys618Ala variant in MLH1 in 1034
individuals (373 sporadic CRC patients, 250 index
subjects from families suspected of having LS [revised
Bethesda Guidelines] and 411 controls). The controls
were selected from the same hospitals, had no personal
histories of cancer and had diagnoses unrelated to the
variables of interest. They were matched for age, gender
and race/ethnicity with the sporadic CRC patients.
No familial history of cancer was available from the
control group. Patients diagnosed at an age over 50
years and not referred to Genetic Counselling Units
were considered as sporadic CRC. Samples from spora-
dic CRC patients were obtained from the Elche Univer-
sity Hospital BioBank and the Castellon Provincial
Hospital BioBank. Written consent to be included in the
respective biobanks was obtained from each patient.
CRC patients, as index subjects from families with sus-
picion of LS that attended Genetic Counselling at the
Cancer Units of the Elche and La Fe Hospitals, were
recruited. The study was approved by the Ethics Com-
mittee of the Elche University Hospital.
The median age of patients in the sporadic CRC group
was 70 years (range, 52-93 years), 47 years (range, 21-87
years) for the familial group and 71 years (range, 25-96
years) for the controls. The sex distribution was 58%
men and 42% women for the sporadic CRC group and
53.3% men and 46.7% women for the controls.
Families carrying the p.Lys618Ala variant
Three characterized LS families that fulfilled the
Amsterdam II Criteria and that consisted of members
with the p.Lys618Ala variant were included to assess co-
occurrence and co-segregation. Two families attended
the Genetic Counselling in Cancer Units of the Elche
and La Fe Hospitals and one family was a member of
the EPICOLON cohort [7].
Concomitant deleterious variants were detected in two
of the families: one in the MLH1 gene (c.676C>T; p.
Arg226X) and the other in the MSH6 gene (c.3013C>T;
p.Arg1005X). Seventeen affected and unaffected family
members from these two families were tested for the
pathogenic and p.Lys618Ala variants.
Genotyping of the MLH1 p.Lys618Ala variant
DNA from blood cells (familial cancer cases and con-
trols) or colorectal mucosa of normal appearance
(sporadic cases) was used for the c.1852_1853AA>GC
variant genotyping. This was assessed using the iPLEX
Gold method (Sequenom, CA, USA), in which single-
base extension and MALDI-TOF technology are
employed for allelic discrimination. These experiments
were carried out at the Centro Español de Genotipado
(CEGEN) genotyping platform facilities. Quality control
for genotyping was conducted by direct sequencing of
familial cancer subjects who underwent genetic analysis
for MLH1 (49/1034, 4.7%).
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Microsatellite instability and MLH1 immunohistochemical
expression
A subset of colorectal tumour DNA samples from 17
patients carrying the p.Lys618Ala variant (eight from
the familial group and nine from the sporadic CRC
group) was screened for MSI status using five mononu-
cleotide markers (BAT26, BAT25, NR21, NR24 and
NR27) and multiplex PCR as previously described by
Buhard et al [8].
Tumours from p.Lys618Ala carrier cases in the famil-
ial group (seven index subjects and one relative) were
also analysed for MLH1 protein expression using immu-
nohistochemistry and anti-MLH1 antibodies (PharMin-
gen, CA, USA) as described elsewhere [7]. Tumour cells
were judged negative for protein expression only if they
lacked staining in a sample in which normal colonocytes
and stroma cells were stained. If no immunostaining of
normal tissue could be demonstrated, the results were
considered unreliable.
MLH1 promoter hypermethylation by Methylation
Sensitive Multiplex Ligation-dependent Probe Amplifica-
tion (MS-MLPA), and BRAF p.Val600Glu mutation by
direct sequencing from tumor DNA was also assess
when MLH1 loss of expression was detected.
Statistical analysis
Hardy-Weinberg equilibrium was calculated for the con-
trol, sporadic CRC and familial CRC groups. Allelic and
genotype frequencies were calculated. In the case-con-
trol study of sporadic CRC, we estimated the odds ratio
(OR) and 95% confidence interval (95% CI) for the p.
Lys618Ala variant using unconditional logistic regression
adjusted for age and sex. We analysed for potential
effect modification by age using an analysis stratified
according to median age at diagnosis for the sporadic
CRC cases (≤70 years or >70 years). A c2 test was used
to evaluate differences in p.Lys618Ala carrier frequen-
cies between the tumour and control groups. A prob-
ability level of <0.05 was considered significant.
Results
No discordances were detected in the genotyping quality
control. The genotype distributions in the control,
sporadic and familial CRC populations did not deviate
significantly from that expected for a population in
Hardy-Weinberg equilibrium (Table 1).
Twenty-seven individuals were heterozygous for the p.
Lys618Ala variant (Figure 1); 11 were controls (11/411,
2.68%), nine were CRC patients from the sporadic group
(9/373, 2.41%) and seven were CRC patients from the
familial group (7/250, 2.8%). None of the individuals
was homozygous for the minor allele.
There were no significant associations in the case-con-
trol and case-case studies (80% detection power, OR =
3.0; two-sided test, alpha level = 5%) (Table 2) and no
statistically significant associations when the OR was
adjusted for age and sex.
In one of the families with LS, the index subject was
heterozygous for a pathogenic MLH1 variant (c.767C>T;
p.Arg226X) and the p.Lys618Ala variant. Two of his off-
spring, who were diagnosed with CRC at the ages of 36
and 39 years, carried the deleterious variant but not the
p.Lys618Ala variant. An unaffected daughter (III-12)
carried the p.Lys618Ala variant but not the deleterious
variant. Two nephews (III-3; III-4) were also diagnosed
with CRC at the ages of 30 and 42 years and they car-
ried only the deleterious variant. Two other healthy
nephews (III-6; III-7) had the wild types of the two var-
iants (Family #1, Figure 2).
In the second LS family, the index subject, one sister
and one brother with CRC (II-5; II-6; II-7, respectively)
had a deleterious variant in MSH6 (c.3013C>T; p.
Arg1005X) but did not have the p.Lys618Ala variant.
This variant was present in only three of four unaffected
Table 1 Allelic and genotypic frequencies and Hardy-
Weinberg equilibrium
Controls
n = 411
Sporadic CRC
n = 373
Familial CRC*
n = 250
Total
n = 1034
Allele
frequencies
AA
GC
0.9866
0.0134
0.9879
0.0121
0.9860
0.0140
0.9869
0.0131
Genotype
frequencies
AA/AA
AA/GC
GC/GC
0.9732
0.0268
0
0.9759
0.0241
0
0.9720
0.0280
0
0.9739
0.0261
0
HW
equilibrium
(p)
0.9639 0.9706 0.9698 0.9448
*Individuals from apparently unrelated families.
wt
p.Lys618Ala
A B
Figure 1 Results of genotyping for the p.Lys618Ala variant
using the iPLEX Sequenom (A) and sequencing (B) methods.
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nephews (III-2; III-3; III-4) and was inherited from the
parental branch, in which there was no familial history of
cancer. Individuals III-3 and III-4 inherited also the dele-
terious variant. No genetic testing was available from the
father or paternal relatives (Family #2, Figure 3).
The p.Lys618Ala variant was present in the third
family that fulfilled the Amsterdam II Criteria. A first-
grade familiar non-carrier of this variant was diagnosed
with a colonic polyp with a high grade of dysplasia at
the age of 39 years and with four colonic polyps at the
age of 42 years (Family #3, Figure 4).
Of the 17 CRC patients with the Lys618Ala variant,
two had MSI (11.8%), one in the familial CRC group
(1/8) and one in the sporadic CRC group (1/9).
The MSI-positive patient from the familial CRC group
showed loss of immunohistochemical expression of
MLH1. This is the index subject (II-3) for the third
family (Figure 4) and no hypermethylation of MLH1
gene promoter; no BRAF p.Val600Glu mutation were
detected in this case.
Discussion
The accelerated development of genetic counselling in
cancer during the past few years is due to the feedback
and interactive information sharing on genetic studies,
clinical management and psychological issues in families
with a high risk of cancer. Identification of deleterious
variants in such families is essential for accurate assess-
ment of individual risk and, if required, subsequent inclu-
sion into a personalized surveillance programme.
Unfortunately, genetic testing for hereditary cancer
frequently fails to identify unambiguous deleterious var-
iants. Erroneous classification of a genetic variant may
have a great effect on at-risk familial who undergo
genetic testing for risk prediction because it results in
incorrect clinical recommendations.
LS is the most common hereditary CRC-predisposing
syndrome and accounts for 3% of unselected CRC cases.
A significant proportion of DNA variations found in
patients suspected of having LS are UVs (32%, 18% and
38% for MLH1, MSH2 and MSH6, respectively) [6]. The
pathogenicity of the MLH1 p.Lys618Ala variant remains
controversial because of conflicting data [InSiGHT,
http://www.insight-group.org] (Figure 5).
The p.Lys618Ala substitution replaces a charged amino
acid with a neutral one, and occurs alongside four
charged amino acids that are well conserved in mammals.
In silico predictions of the pathogenicity of this variant
using the PolyPhen http://genetics.bwh.harvard.edu/pph/
and SIFT http://sift.jcvi.org/ computational program
Table 2 Results of case-control and case-case analyses.
Odds ratios (ORs) and 95% confidence intervals (95%
CIs) for the p.Lys618Ala variant
Sporadic vs
Controls
Familial vs
Controls
Sporadic vs
Familial
OR
[95% CI]
0.899 [0.378-2.139] 1.048 [0.414-2.655] 0.955 [0.377-2.417]
p value 1 1 1
CRC (69y)
4
CRC (dx30y)
CRC (dx68y)
DC (dx76y)
GC (dx40y)
37yCRC (dx36y)
CRC (dx39y)
46y
CRC (dx39y)
44y
42y 39y 30y
CRC (dx30y)
CRC CRC (dx30y) CRC (dx42y) 50y 48y
16y 12y
I
II
III
IV
1               2                                   3                4                     5                                 6                 7               
1               2
1      2             3                 4                5       6             7                      8                 9     10            11           12            13
1                                       2            3
: Mutation carrier
: UV carrier
or       : Non carrier
Figure 2 Pedigree for Family #1 (CRC: Colorectal cancer; GC: Gastric cancer; DC: Duodenal cancer).
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were discordant; the SIFT analysis classified it as a toler-
ant variant and the PolyPhen analysis classed it as possi-
bly damaging [9]. It has been shown that this variant may
reduce the binding ability of MLH1 to PMS2 in HCT116
cells co-transfected with mutated MLH1 and wild-type
PMS2 [10]. In contrast, it had no effect on the ability of
MLH1 to bind PMS2 in a co-immunoprecipitation assay
[9]. Functional analysis using the pCAS ex vivo splicing
assay and RNA analysis also demonstrated no effect [11].
Moreover, a significant decrease in MLH1 protein stabi-
lity has been found for the p.Lys618Ala variant [9].
The results of in silico prediction and functional
assays alone are insufficient to determine whether this
variant is deleterious or a rare functional polymorphism.
CRC (†42y) CRCEC (†54y)
CRC
CRC (dx53y)
CRC (dx60y)
†61y
3
I
II
III
1                      2                 3                4                     5                     6                      7               
1                2
1           2             3            4
: Mutation carrier
: UV carrier
or       : Non carrier
Figure 3 Pedigree for Family #2 (CRC: Colorectal cancer; EC: Endometrial cancer).
• 1 colonic polyp with high 
grade of dysplasia (2008)
• 4 colonic polyps (2009)
42y
CRC (†71y)
CRC (dx45y)
49y
ESC (dx48y)
†49y
27y
LC (†70y) CRC (†70y)
22y
CRC (dx59y)
65y
2
5
I
II
III
1            2                     3                         4                5                 
1                2               3                          4                                                                10              11
1                2
: UV carrier
: Non carrier
Figure 4 Pedigree for Family #3 (CRC: Colorectal cancer; ESC: Oesophageal cancer; LC: Lung cancer).
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For this purpose, it is necessary to integrate indirect evi-
dence with direct genetic evidence involving clinical
observations of disease occurrence.
The frequency of variants in unaffected controls is
used often to distinguish between neutral and poten-
tially deleterious variants. If the frequency of a variant
among a few hundred controls is ≥1%, it is highly unli-
kely to be a high-risk variant. In such cases, it is still
possible that the variant will be associated with a mod-
est risk of the disease [3]. Case-control studies enable
quantification of the disease risk associated with the var-
iant. The main disadvantage of such analyses is that a
large sample size is required to obtain sufficient power
to detect the lower risk level. The sample size required
is related inversely to the frequency of the variant in the
population. The sample size used in the present study
resulted in 80% power to detect an OR of 3.0 (two-sided
test; alpha level, 5%). The frequency of the p.Lys618Ala
variant in our control series was 2.7% and no significant
differences were observed in the sporadic and familial
groups, indicating that a high penetrance effect for col-
orectal carcinogenesis can be excluded. Similar results
were reported in case-control studies on Scottish and
Danish populations [12,13].
As most disease pedigrees are small, it is difficult to
obtain a sufficient number of samples from affected and
informative unaffected individuals. Moreover, LS dele-
terious variants are not completely penetrant. For these
reasons, it is rarely possible to categorize variants as
deleterious based on segregation alone. The co-occur-
rence of another known deleterious variant reduces the
likelihood that an UV is truly deleterious, especially
when both variants are located in trans [3]. To our
knowledge, co-occurrence of a deleterious variant in one
of the LS genes with the p.Lys618Ala variant has been
observed in only two families. Liu et al [14] described
an index subject from a LS family with two heterozy-
gous variants (c.546-2A>G and c.1852_1853AA>GC);
only the former segregated with LS in the family. Simi-
larly, Steinke et al [15], described the co-occurrence of
the p.Lys618Ala (c.1852_1853AA>GC) variant with the
MSH6 p.Arg1068X (c.3202C>T) deleterious variant.
Herein, we describe the coexistence of the p.Lys618Ala
variant with deleterious variants in another two unrelated
LS families. In one family, the allele distribution of the
pathogenic and unclassified variant was in trans, in the
other family the pathogenic variant was detected in the
MSH6 gene and only the deleterious variant co-segre-
gated with the disease in both families. This evidence
indicates that the p.Lys618Ala variant is not deleterious.
The molecular hallmark of LS tumours is an MSI phe-
notype, a functional consequence of MMR deficiency. It
is expected that the putative germ-line mutation respon-
sible for LS would confer the MSI phenotype. We tested
the MSI status of 17 tumours from p.Lys618Ala carriers
and detected only two cases of MSI (11.8%). Taking into
consideration the bias caused by the over-representation
of Bethesda Criteria-positive tumours in this subset of
cases (8/17), the MSI frequency was not significantly dif-
ferent from that in the unselected CRC group [7]. This is
further proof that the presence of this variant is irrelevant
to the functional inactivation of MLH1 in CRC patients.
Nonetheless, we cannot exclude the possibility that
this variant may result in a small increase in susceptibil-
ity to CRC or adenomas, as was suggested by Fearnhead
et al [16]. Further studies with appropriate sample sizes
are required to address the low penetrance effect of this
variant in CRC.
Finally, we hypothesize that the clinical significance of a
genetic variant may differ according to genetic back-
ground. Gene functionality may be the net result of the
effects of allelic structures and their interactions with
environmental factors. It is possible that low-penetrance
variants behave differently in different populations, making
it difficult to make predictions in terms of conferred risk.
Conclusions
Taken together, the results of this study and others indi-
cate that the c.1852_1853AA>GC variant should be con-
sidered a neutral variant for LS. These findings have
considerable relevance for the clinical management of
CRC probands and their relatives.
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